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Abstract
Circulating natriuretic peptides are useful biomarkers of left ventricular dysfunction and heart failure
in the general population. Cardiac troponin T (cTnT) is also considered a sensitive marker of
myocardial injury. However, the fact that levels of circulating natriuretic peptides and cTnT are
almost invariably increased in end-stage renal disease patients has been considered a major limitation
for their use as diagnostic or prognostic tools in this population. We provide an updated review on
the role of natriuretic peptides and cTnT as biomarkers in predicting outcome and treatment in the
hemodialysis population.
Introduction and context
Cardiovascular disease is the leading cause of mortality
in patients with end-stage renal disease (ESRD) and is
partly attributed to the very high prevalence of left
ventricular (LV) abnormalities, including LV hypertro-
phy, systolic dysfunction and congestive heart failure.
The Kidney Disease Outcome Quality Initiative
(KDOQI) guidelines have, therefore, made the recom-
mendation that echocardiography be performed at
initiation of dialysis in all ESRD patients and every
3 years thereafter [1]. However, echocardiography services
are very often stretched in hospitals and not routinely
performed in most dialysis centers. Therefore, circulating
biomarkers that identify patients with subclinical heart
disease or diseased myocardium may have a potentially
important clinical value in allowing early detection,
intervention and possibly ongoing surveillance of high-
risk patients. In recent years, the natriuretic peptides have
emerged as promising cardiac biomarkers in this aspect.
The B-type, or brain natriuretic peptide (BNP) is a 32
amino acid peptide hormone predominantly released
from the ventricles in response to LV volume expansion
and pressure overload [2–4] and has a circulating half-
life of 23 minutes. N-terminal pro-BNP (NT-pro-BNP) is
a 76 amino acid peptide hormone also cleaved from the
prohormone; it is biologically inactive but has a much
longer half-life (120 minutes). BNP levels are well
known to correlate with LV filling pressures and are
elevated in patients with LV dysfunction [2,5]. Both BNP
and NT-pro-BNP levels increased in proportion to the
severity of heart failure as assessed using the New York
Heart Association classification in the general popula-
tion [6,7]. In patients without chronic kidney disease
(CKD), BNP and NT-pro-BNP testing are found to be
most useful in ruling out the diagnosis of heart failure in
those presenting with dyspnoea [8–11]. The value of
BNP or NT-pro-BNP testing in predicting prognosis has
also been established in the general population [12].
In stage 5 CKD patients receiving hemodialysis or
peritoneal dialysis, BNP and NT-pro-BNP are almost
invariably increased compared to normal cutoffs [13–
19]. These elevations were partly attributed to decreased
renal clearance, chronic volume overload as well as to the
very high prevalence of cardiac abnormalities [13–19].
NT-pro-BNP has been shown to be inversely related to
residual renal function in both hemodialysis and
peritoneal dialysis patients [15,16]. A study in the non-
ESRD population also confirmed renal dysfunction as a
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BNP in the absence of LV systolic dysfunction [20]. Thus,
in dialysis patients, BNP and NT-pro-BNP levels have to
be interpreted in light of the presence or absence of
residual renal function. BNP and NT-pro-BNP have been
shown to be strongly associated with LV hypertrophy
and dilation, and systolic dysfunction, in both hemo-
dialysis and peritoneal dialysis patients [14–19]. NT-pro-
BNP was also associated with coronary artery disease in
non-dialysis CKD patients [21].
On the other hand, cardiac troponin T (cTnT) is a
sensitive marker of myocardial injury and is the current
gold standard test for diagnosis of acute myocardial
necrosis in the general population. However, levels of
cTnT are frequently elevated in the absence of acute
coronary syndrome among patients with varying degrees
of kidney disease [22–28]. Using the 99
th percentile
cutoff of 0.1 μg/L, the prevalence of cTnT elevation was
reported to range from 30 to 85% in ESRD patients [22–
27]. This led to the initial suggestion that cTnT may have
limited diagnostic or prognostic value in patients with
CKD. In the GUSTO IV (Global Use of Strategies to Open
Occluded Coronary Arteries IV) trial, elevated cTnT was
strongly predictive of poor short-term prognosis irre-
spectiveof creatinine clearance in patients with suspected
acute coronary syndrome [29]. Notably, cTnT elevation
had even greater prognostic importance among patients
with mild to moderate degrees of kidney disease, clearly
confirming the specificity of cTnT as a marker of
myocardial injury among patients with kidney disease.
There is robust evidence that cTnT is a powerful
prognostic marker in ESRD patients. One of the earliest
and largest studies, by Apple et al. [26], showed that an
elevated cTnT>99
th percentile cutoff was predictive of
both short-term and long-term mortality in hemodia-
lysis patients. Numerous other studies have demon-
strated similar prognostic importance of cTnT in
hemodialysis patients [22–25,27].
Recent advances
Diagnostic value of BNP or NT-pro-BNP for LV systolic
dysfunction in hemodialysis patients
In a recent small study, a serum NT-pro-BNP cutoff
≥7200 ng/L was suggested to be useful in diagnosing LV
systolic dysfunction in hemodialysis patients, regardless
of the patients’ fluid status, with a specificity of 90% and
a sensitivity of 79%. Further reducing the cutoff to
approximately 5000 ng/L increased the sensitivity in
diagnosing LV systolic dysfunction to >90% but reduced
the specificity to 80% [30]. This observation was very
similar to the earlier Cardiovascular Risk Evaluation
Extension (CREED) study, suggesting the potential value
of BNP testing in ruling out systolic dysfunction in the
dialysis population [14]. However, the best cutoff of BNP
or NT-pro-BNP in diagnosing or ruling out systolic
dysfunction will need stratification according to residual
renal function and will require further confirmation in a
larger cohort of the dialysis population. Notably, in
patients with LV systolic dysfunction, persistent post-
dialytic volume overload was significantly related to
serum levels of NT-pro-BNP [30]. A number of other
studies reported similar correlations between markers of
hypervolemia and high plasma BNP or NT-pro-BNP
[31,32]. However, so far there are no convincing data to
suggest that BNP or NT-pro-BNP represent useful
markers of volume status in hemodialysis patients
[16,33].
Prognostic value of baseline BNP and NT-pro-BNP in
dialysis patients
BNP and NT-pro-BNP are increasingly recognized to be
powerful predictors of mortality and cardiovascular
death in the dialysis population. In one of the earliest
prospective cohort studies, performed in 399 hemodia-
lysis patients, NT-pro-BNP was associated with 2-year all-
cause mortality and, in a smaller study, with 3-year
cardiac morbidity and mortality [13]. The CREED study
showed that plasma BNP taken on a non-dialysis day
was predictive of overall and cardiovascular death in
hemodialysis patients [34]. A more recent study by
Madsen et al. [16] also showed that both pre- and post-
hemodialysis NT-pro-BNP were predictive of 2-year
mortality. These data clearly suggested that levels of
BNP and NT-pro-BNP had powerful prognostic implica-
tions irrespective of whether the measurement was taken
before, shortly after or in-between dialysis. One study
showed that both pre- and post-dialysis BNP and NT-
pro-BNP were strongly correlated [35]. However, given
that levels of BNP and NT-pro-BNP were altered by
hemodialysis [16,35], it is important to standardize the
timing of measurement of BNP or NT-pro-BNP in
relation to the dialysis session in hemodialysis patients.
In peritoneal dialysis patients, NT-pro-BNP was predic-
tive of long-term (3 years) all-cause mortality, cardio-
vascular death and events as well as cardiovascular
congestion independent of echocardiographic measures
of LV mass and ejection fraction [15]. Post hoc analysis
from the Adequacy of Dialysis in Mexico (ADEMEX)
study also showed a similar finding that the baseline NT-
pro-BNP level was independently predictive of overall
survival and cardiovascular death in peritoneal dialysis
patients, irrespective of treatment arm [36].
A recent study compared the prognostic value of NT-pro-
BNP and cTnT in hemodialysis patients and showed that
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dysfunction and was indeed more strongly associated
with mortality than cTnT [17]. However, the combina-
tion of cTnT and NT-pro-BNP did not improve the
association with all-cause and cardiovascular mortality
compared to NT-pro-BNP alone. NT-pro-BNP was a
marker of mortality even after adjusting for LV mass
index and midwall fractional shortening. These data
suggest that NT-pro-BNP may be a more powerful
prognostic marker compared to cTnT.
Role of serial monitoring of NT-pro-BNP for outcome
prediction in dialysis patients
More recently, a prospective cohort study performed in
2,990 incident hemodialysis patients reported similar
findings; increased NT-pro-BNP level was independently
associated with increased risk of mortality at 90 days and
1 year [37]. Furthermore, in a smaller subset of 585
incident hemodialysis patients, repeat measurement of
NT-pro-BNP was performed at 3 months. Patients with
the greatest increase in NT-pro-BNP after 3 months of
dialysis showed a 2.4-fold higher risk of mortality than
those with the greatest decrease in NT-pro-BNP. These
data for the first time suggested that serial changes in NT-
pro-BNP levels also carried important prognostic infor-
mation, independent of baseline NT-pro-BNP level, and
were predictive of subsequent mortality [37].
Notably, in the recent post hoc analysis of the German
Diabetes Dialysis Study (4D Study), which evaluated
atorvastatin in 1,255 type 2 diabetic ESRD patients on
maintenance hemodialysis, it was found that increased
NT-pro-BNP over at least a 6-month period was strongly
predictive of an increased risk of sudden death,
cardiovascular event and mortality. Doubling of NT-
pro-BNP was associated with a 46% increase in the risk
of death. Furthermore, the increased risk of mortality
with rising NT-pro-BNP was independent of baseline
NT-pro-BNP and baseline co-morbidity [38].
Prognostic value of cardiac troponin T in dialysis patients
In a recent meta-analysis based on 28 studies published
between 1999 and 2004 and including 3,931 patients,
cTnT was shown to be a useful risk stratification tool in
the ESRD population. The pooled analysis indicated that
an elevated cTnT (>0.1 μg/L) is useful in identifying a
subgroup of asymptomatic ESRD patients with poor
survival and a higher risk of cardiac death [39]. Recently,
the Food and Drug Administration has approved the use
of cTnT as a biomarker for mortality risk stratification in
ESRD patients. Similarly, the use of cTnT for predicting
prognosis has also been recommended by the KDOQI
[1]. Of note, the NECOSAD (Netherlands Cooperative
Study on the Adequacy of Dialysis) showed only limited
added predictive power of cTnT over other clinical risk
factors in a combined cohort of hemodialysis and
peritoneal dialysis patients [40]. This observation was
somewhat contrary to our recent finding that cTnT had a
significant additional value for prognostication beyond
the standard clinical, biochemical, dialysis and echocar-
diographic measures, including LV mass and ejection
fraction in chronic peritoneal dialysis patients [41]. More
importantly, our study showed that the prognostic value
of cTnT was independent of inflammation, residual renal
function, LV hypertrophy and dysfunction, clearly
supporting the additional value of measuring cTnT for
early identification of high-risk ESRD patients. A recent
study also showed that cTnT is a useful biomarker in
predicting the development of circulatory congestion in
chronic peritoneal dialysis patients [42]. These data
suggest that cTnT serves as an important adjunct to
echocardiography in identifying peritoneal dialysis
patients at risk of circulatory congestion. Whether the
findings are also applicable to hemodialysis patients
requires further evaluation.
Mechanisms of elevated cTnT in dialysis patients
Elevated cTnT has been linked to LV hypertrophy, LV
dilation, diabetes, and impaired systolic and diastolic
dysfunction in hemodialysis patients [43–45]. There is
evidence that elevated cTnT in asymptomatic ESRD
patients reflects subclinical myocardial injury. Ooi et al.
[46] showed that elevated cTnT was invariably associated
with pathological evidence of old, recent or healing
myocardial necrosis or micro-infarction. In another
study, cTnT elevation was closely correlated with the
severity of angiographic coronary artery disease in
chronic hemodialysis patients [47]. cTnT elevation has
also been linked to the degree of coronary artery
calcification in asymptomatic hemodialysis patients
[48]. Even though cTnT was significantly confounded
by residual kidney function [41], circulating cTnT in
patients with kidney failure was noted to be predomi-
nantly the free-intact form, as in patients with acute
coronary syndrome [49]. This was important evidence to
support that circulating cTnT in ESRD patients is indeed
a marker of cardiac pathology. Given that free and bound
cTnT are both relatively large molecules of 37 and
77kDa, respectively, elevated cTnT in ESRD patients is
unlikely to be the result of decreased renal clearance.
Using contrast magnetic resonance imaging, a recent
study showed that elevated cTnT cannot be solely
attributed to previous subclinical myocardial necrosis
or LV hypertrophy [50]. It was speculated that additional
myocardial pathologies, such as myocardial fibrosis,
may contribute to increased cTnT in ESRD patients and
require further evaluation.
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Clinical utility of BNP/NT-pro-BNP in hemodialysis
patients
Together, these data suggest that serial monitoring of NT-
pro-BNP levels may represent a novel and useful clinical
tool in guiding treatment efficacy in the dialysis
population and warrant further investigation. Treatment
guided by lowering plasma NT-pro-BNP levels has been
shown to reduce cardiovascular events and delay time to
first cardiovascular event, compared with usual clinically
guided treatment in patients with chronic heart failure
[51]. A BNP-guided strategy has also been shown to
reduce the risk of heart-failure related death or length of
hospital stay for heart failure, compared to standard
clinical care in the general population [52]. In a recent
small prospective study of 21 stable hemodialysis
patients with preserved systolic function, changes in LV
mass index over 6-month and 12-month periods were
closely correlated with changes in NT-pro-BNP levels
[53]. All these observations prompt further investigation
into the application of serial BNP and NT-pro-BNP
monitoring as biomarkers for assessing changes in LV
mass index or systolic function in hemodialysis patients.
Whether BNP or NT-pro-BNP guided therapy may be
useful in monitoring treatment efficacy and improving
clinical outcomes of hemodialysis patients needs further
prospective evaluation.
Clinical utility of cTnT in hemodialysis patients
How can cTnT testing be applied in daily clinical
practice? Given that cTnT is confounded by residual
kidney function, we believe a baseline level should first
be obtained in all hemodialysis patients in order to
distinguish subsequent cTnT elevation due to acute
coronary syndrome and/or chronic myocardial injury.
The measurement should best be obtained before
dialysis because cTnT levels may increase post-dialysis
[54]. A baseline level not only allows outcome prediction
and identifies high-risk patients, but also forms an
important basis to evaluate changes over time. Our
recent data suggested that even minimally increased cTnT
is associated with an increased risk of mortality and
cardiovascular death in peritoneal dialysis patients [41].
This is well in accord with observations in the general
population suggesting that a minimally increased cTnT
concentration reflects increased cardiovascular risk [55].
According to the recent National Academy of Clinical
Biochemistry (NACB) laboratory medicine practice
guidelines, measurement of cardiac troponins should
also be used to evaluate acute coronary syndrome in
ESRD patients [56]. In ESRD patients who present with
possible acute coronary syndrome, a dynamic change in
cardiac troponins of ≥ 20% after presentation should be
used to define acute coronary syndrome. In addition,
testing for cardiac troponins may be used as an aid in
defining the risk of mortality in ESRD patients. Whether
c T n Tt e s t i n gm a yb eau s e ful screening test for
cardiovascular disease in the hemodialysis population
warrants further evaluation.
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